Equity Research, Broker Reports, and media content on SANTHERA PHARMACEUTICALS-REG etc.

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about SANTHERA PHARMACEUTICALS-REG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree offers SANTHERA PHARMACEUTICALS-REG research coverage from 0 professional analysts, and we have 0 reports on our platform.

Our simple but effective charting function allows for a quick scan of SANTHERA PHARMACEUTICALS-REG's performance over multiple time horizons.

Date Source Announcement
04/10/2016 06:01:00 GlobeNewswire Santhera announces appointment of Kristina Timdahl as Chief Medical Officer and Head of Development as of January 2017
28/09/2016 06:00:00 GlobeNewswire Santhera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids
13/09/2016 06:00:00 GlobeNewswire Leading medical journal publishes treatment effect of Santhera's Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD)
08/09/2016 06:00:00 GlobeNewswire Santhera's Idebenone (Raxone) Receives Orphan Drug Designation for Duchenne Muscular Dystrophy in Australia
06/09/2016 06:00:00 GlobeNewswire Santhera Announces Financial Results for the First Half Year 2016 and Reports Solid Sales Growth - Company Starts to Build US Operations and Strengthens Board of Directors
30/08/2016 06:00:00 GlobeNewswire Santhera Receives FDA Grant in Support of its Ongoing Phase I Trial with Omigapil in Congenital Muscular Dystrophy
29/08/2016 06:00:00 GlobeNewswire Santhera to Report Half-Year 2016 Financial Results on Tuesday, September 6, 2016
  • Frequency of research reports